Inhibitors | Comment | Organism | Structure |
---|---|---|---|
etomoxir | regional differences in brain fatty acid oxidation may be blocked by irreversible CPT1a inhibitor etomoxir; regional differences in brain fatty acid oxidation may be blocked by irreversible CPT1a inhibitor etomoxir | Rattus norvegicus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Rattus norvegicus | P18886 | isoform CPT2 | - |
Rattus norvegicus | P32198 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
astrocyte | isoforms CPT1a and CPT2 are expressed exclusively by astrocytes | Rattus norvegicus | - |
brain | brain isoform CPT1a RNA and total protein expression are unchanged throughout post-natal development (PND0, PND7, PND14, PND21 and PND50). Acylcarnitines, generated by CPT1a, significantly increase with age and peak at PND21 in all brain regions, concurrent with the increased expression of enzymes involved in mitochondrial beta-oxidation | Rattus norvegicus | - |
brain | brain isoform CPT2 RNA peaks at post-natal day 21 and remains unchanged through post-natal day 50 in all regions studied. CPT2 transcript abundance is highly developmentally regulated in the cortex, midbrain, and cerebellum, and significantly increases with age. The peak of acylcarnitine abundance in all brain regions profiled at post-natal day 21 corresponds to the maximal expression of CPT2 mRNA | Rattus norvegicus | - |
hippocampus | expression of isoforms CPT1a and CPT2 increases during brain development and is enriched in hippocampus relative to the cortex, midbrain, and cerebellum | Rattus norvegicus | - |
hippocampus | no age differences are detected in CPT2 mRNA expression in hippocampus | Rattus norvegicus | - |